Difference between revisions of "HAEM5:Ataxia-telangiectasia syndrome"

From Compendium of Cancer Genome Aberrations
Jump to navigation Jump to search
VisualWikitext
[unchecked revision][checked revision]
(Created page with "{{DISPLAYTITLE:Ataxia-telangiectasia syndrome}} Haematolymphoid Tumours (5th ed.) {{Under Construction}} ==Primary Author(s)*== Put your text her...")
 
 
(4 intermediate revisions by 2 users not shown)
Line 1: Line 1:
 
{{DISPLAYTITLE:Ataxia-telangiectasia syndrome}}
 
{{DISPLAYTITLE:Ataxia-telangiectasia syndrome}}
 +
 
[[HAEM5:Table_of_Contents|Haematolymphoid Tumours (5th ed.)]]
 
[[HAEM5:Table_of_Contents|Haematolymphoid Tumours (5th ed.)]]
  
−
{{Under Construction}}
 
−
==Primary Author(s)*==
 
−
 
−
Put your text here<span style="color:#0070C0"> (''Name and affiliation; example:'' Jane Smith, PhD, Institute of Genomics) </span>
 
−
 
−
__TOC__
 
−
 
−
==Cancer Category/Type==
 
−
 
−
Put your text here
 
−
 
−
==Cancer Sub-Classification / Subtype==
 
−
 
−
Put your text here
 
−
 
−
==Definition / Description of Disease==
 
−
 
−
Put your text here <span style="color:#0070C0">(''Instructions: Brief description of approximately one paragraph - include disease context relative to other WHO classification categories referring to the specific WHO book pages, diagnostic criteria if applicable, and differential diagnosis if applicable'') </span>
 
−
 
−
==Synonyms / Terminology==
 
−
 
−
Put your text here <span style="color:#0070C0">(''Instructions: Include currently used terms and major historical ones, adding “(historical)” after the latter.'') </span>
 
−
 
−
==Epidemiology / Prevalence==
 
−
 
−
Put your text here
 
−
 
−
==Clinical Features==
 
−
 
−
Put your text here and fill in the table <span style="color:#0070C0">(''Instruction: Can include references in the table'') </span>
 
−
{| class="wikitable"
 
−
|'''Signs and Symptoms'''
 
−
|EXAMPLE Asymptomatic (incidental finding on complete blood counts)
 
−
 
−
EXAMPLE B-symptoms (weight loss, fever, night sweats)
 
−
 
−
EXAMPLE Fatigue
 
−
 
−
EXAMPLE Lymphadenopathy (uncommon)
 
−
|-
 
−
|'''Laboratory Findings'''
 
−
|EXAMPLE Cytopenias
 
−
 
−
EXAMPLE Lymphocytosis (low level)
 
−
|}
 
−
 
−
==Sites of Involvement==
 
−
 
−
Put your text here <span style="color:#0070C0">(''Instruction: Indicate physical sites; Example: nodal, extranodal, bone marrow'') </span>
 
−
 
−
==Morphologic Features==
 
−
 
−
Put your text here
 
−
 
−
==Immunophenotype==
 
−
 
−
Put your text here and fill in the table <span style="color:#0070C0">(''Instruction: Can include references in the table'') </span>
 
−
 
−
{| class="wikitable sortable"
 
−
|-
 
−
!Finding!!Marker
 
−
|-
 
−
|Positive (universal)||EXAMPLE CD1
 
−
|-
 
−
|Positive (subset)||EXAMPLE CD2
 
−
|-
 
−
|Negative (universal)||EXAMPLE CD3
 
−
|-
 
−
|Negative (subset)||EXAMPLE CD4
 
−
|}
 
−
 
−
==Chromosomal Rearrangements (Gene Fusions)==
 
−
 
−
Put your text here and fill in the table
 
−
 
−
{| class="wikitable sortable"
 
−
|-
 
−
!Chromosomal Rearrangement!!Genes in Fusion (5’ or 3’ Segments)!!Pathogenic Derivative!!Prevalence
 
−
!Diagnostic Significance (Yes, No or Unknown)
 
−
!Prognostic Significance (Yes, No or Unknown)
 
−
!Therapeutic Significance (Yes, No or Unknown)
 
−
!Notes
 
−
|-
 
−
|EXAMPLE t(9;22)(q34;q11.2)||EXAMPLE 3'ABL1 / 5'BCR||EXAMPLE der(22)||EXAMPLE 20% (COSMIC)
 
−
EXAMPLE 30% (add reference)
 
−
|Yes
 
−
|No
 
−
|Yes
 
−
|EXAMPLE
 
−
 
−
The t(9;22) is diagnostic of CML in the appropriate morphology and clinical context (add reference). This fusion is responsive to targeted therapy such as Imatinib (Gleevec) (add reference).
 
−
|}
 
−
 
−
==Individual Region Genomic Gain/Loss/LOH==
 
−
 
−
Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: Includes aberrations not involving gene fusions. Can include references in the table. Can refer to CGC workgroup tables as linked on the homepage if applicable.'') </span>
 
−
 
−
{| class="wikitable sortable"
 
−
|-
 
−
!Chr #!!Gain / Loss / Amp / LOH!!Minimal Region Genomic Coordinates [Genome Build]!!Minimal Region Cytoband
 
−
!Diagnostic Significance (Yes, No or Unknown)
 
−
!Prognostic Significance (Yes, No or Unknown)
 
−
!Therapeutic Significance (Yes, No or Unknown)
 
−
!Notes
 
−
|-
 
−
|EXAMPLE
 
−
 
−
7
 
−
|EXAMPLE Loss
 
−
|EXAMPLE
 
−
 
−
chr7:1- 159,335,973 [hg38]
 
−
|EXAMPLE
 
−
 
−
chr7
 
−
|Yes
 
−
|Yes
 
−
|No
 
−
|EXAMPLE
 
−
 
−
Presence of monosomy 7 (or 7q deletion) is sufficient for a diagnosis of AML with MDS-related changes when there is ≥20% blasts and no prior therapy (add reference).  Monosomy 7/7q deletion is associated with a poor prognosis in AML (add reference).
 
−
|-
 
−
|EXAMPLE
 
−
 
−
8
 
−
|EXAMPLE Gain
 
−
|EXAMPLE
 
−
 
−
chr8:1-145,138,636 [hg38]
 
−
|EXAMPLE
 
−
 
−
chr8
 
−
|No
 
−
|No
 
−
|No
 
−
|EXAMPLE
 
−
 
−
Common recurrent secondary finding for t(8;21) (add reference).
 
−
|}
 
−
==Characteristic Chromosomal Patterns==
 
−
 
−
Put your text here <span style="color:#0070C0">(''EXAMPLE PATTERNS: hyperdiploid; gain of odd number chromosomes including typically chromosome 1, 3, 5, 7, 11, and 17; co-deletion of 1p and 19q; complex karyotypes without characteristic genetic findings; chromothripsis'')</span>
 
−
 
−
{| class="wikitable sortable"
 
−
|-
 
−
!Chromosomal Pattern
 
−
!Diagnostic Significance (Yes, No or Unknown)
 
−
!Prognostic Significance (Yes, No or Unknown)
 
−
!Therapeutic Significance (Yes, No or Unknown)
 
−
!Notes
 
−
|-
 
−
|EXAMPLE
 
−
 
−
Co-deletion of 1p and 18q
 
−
|Yes
 
−
|No
 
−
|No
 
−
|EXAMPLE:
 
−
 
−
See chromosomal rearrangements table as this pattern is due to an unbalanced derivative translocation associated with oligodendroglioma (add reference).
 
−
|}
 
−
==Gene Mutations (SNV/INDEL)==
 
−
 
−
Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: This table is not meant to be an exhaustive list; please include only genes/alterations that are recurrent and common as well either disease defining and/or clinically significant. Can include references in the table. For clinical significance, denote associations with FDA-approved therapy (not an extensive list of applicable drugs) and NCCN or other national guidelines if applicable; Can also refer to CGC workgroup tables as linked on the homepage if applicable as well as any high impact papers or reviews of gene mutations in this entity.'') </span>
 
−
 
−
{| class="wikitable sortable"
 
−
|-
 
−
!Gene; Genetic Alteration!!'''Presumed Mechanism (Tumor Suppressor Gene [TSG] / Oncogene / Other)'''!!'''Prevalence (COSMIC /  TCGA / Other)'''!!'''Concomitant Mutations'''!!'''Mutually Exclusive Mutations'''
 
−
!'''Diagnostic Significance (Yes, No or Unknown)'''
 
−
!Prognostic Significance (Yes, No or Unknown)
 
−
!Therapeutic Significance (Yes, No or Unknown)
 
−
!Notes
 
−
|-
 
−
|EXAMPLE: TP53; Variable LOF mutations
 
−
 
−
EXAMPLE:
 
−
 
−
EGFR; Exon 20 mutations
 
−
 
−
EXAMPLE: BRAF; Activating mutations
 
−
|EXAMPLE: TSG
 
−
|EXAMPLE: 20% (COSMIC)
 
−
 
−
EXAMPLE: 30% (add Reference)
 
−
|EXAMPLE: IDH1 R123H
 
−
|EXAMPLE: EGFR amplification
 
−
|
 
−
|
 
−
|
 
−
|EXAMPLE:  Excludes hairy cell leukemia (HCL) (add reference).
 
−
<br />
 
−
|}
 
−
Note: A more extensive list of mutations can be found in cBioportal (https://www.cbioportal.org/), COSMIC (https://cancer.sanger.ac.uk/cosmic), ICGC (https://dcc.icgc.org/) and/or other databases. When applicable, gene-specific pages within the CCGA site directly link to pertinent external content.
 
−
 
−
==Epigenomic Alterations==
 
−
 
−
Put your text here
 
−
 
−
==Genes and Main Pathways Involved==
 
−
 
−
Put your text here and fill in the table <span style="color:#0070C0">(''Instructions: Can include references in the table.'')</span>
 
−
{| class="wikitable sortable"
 
−
|-
 
−
!Gene; Genetic Alteration!!Pathway!!Pathophysiologic Outcome
 
−
|-
 
−
|EXAMPLE: BRAF and MAP2K1; Activating mutations
 
−
|EXAMPLE: MAPK signaling
 
−
|EXAMPLE: Increased cell growth and proliferation
 
−
|-
 
−
|EXAMPLE: CDKN2A; Inactivating mutations
 
−
|EXAMPLE: Cell cycle regulation
 
−
|EXAMPLE: Unregulated cell division
 
−
|-
 
−
|EXAMPLE:  KMT2C and ARID1A; Inactivating mutations
 
−
|EXAMPLE:  Histone modification, chromatin remodeling
 
−
|EXAMPLE:  Abnormal gene expression program
 
−
|}
 
−
==Genetic Diagnostic Testing Methods==
 
−
 
−
Put your text here
 
−
 
−
==Familial Forms==
 
−
 
−
Put your text here <span style="color:#0070C0">(''Instructions: Include associated hereditary conditions/syndromes that cause this entity or are caused by this entity.'') </span>
 
−
 
−
==Additional Information==
 
−
 
−
Put your text here
 
−
 
−
==Links==
 
−
 
−
Put your text placeholder here (or anywhere appropriate on the page) and use the "Link" icon at the top of the page <span style="color:#0070C0">(''Instructions: Once you have a text placeholder entered to which you want to add a link, highlight that text, select the "Link" icon at the top of the page, and search the name of the internal page to which you want to link this text, or enter an external internet address including the "<nowiki>http://www</nowiki>." portion.'')</span>
 
−
 
−
==References==
 
−
(use the "Cite" icon at the top of the page) <span style="color:#0070C0">(''Instructions: Add each reference into the text above by clicking on where you want to insert the reference, selecting the “Cite” icon at the top of the page, and using the “Automatic” tab option to search such as by PMID to select the reference to insert. The reference list in this section will be automatically generated and sorted.''</span> <span style="color:#0070C0">''If a PMID is not available, such as for a book, please use the “Cite” icon, select “Manual” and then “Basic Form”, and include the entire reference''</span><span style="color:#0070C0">''.''</span><span style="color:#0070C0">) </span> <references />
 
−
 
−
'''EXAMPLE Book'''
 
−
 
−
#Arber DA, et al., (2017). Acute myeloid leukaemia with recurrent genetic abnormalities, in World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, Revised 4th edition. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Arber DA, Hasserjian RP, Le Beau MM, Orazi A, and Siebert R, Editors. IARC Press: Lyon, France, p129-171.
 
  
−
==Notes==
+
'''See page in GTS5 volume. Linked here:''' [[GTS5:Ataxia-telangiectasia syndrome (ATM)]]
−
<nowiki>*</nowiki>Primary authors will typically be those that initially create and complete the content of a page.  If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the CCGA coordinators (contact information provided on the homepage).  Additional global feedback or concerns are also welcome.
 
−
<nowiki>*</nowiki>''Citation of this Page'': “Ataxia-telangiectasia syndrome”. Compendium of Cancer Genome Aberrations (CCGA), Cancer Genomics Consortium (CGC), updated {{REVISIONMONTH}}/{{REVISIONDAY}}/{{REVISIONYEAR}}, <nowiki>https://ccga.io/index.php/HAEM5:Ataxia-telangiectasia_syndrome</nowiki>.[[Category:HAEM5]][[Category:DISEASE]][[Category:Diseases A]]
 

Latest revision as of 15:08, 12 July 2024


Haematolymphoid Tumours (5th ed.)


See page in GTS5 volume. Linked here: GTS5:Ataxia-telangiectasia syndrome (ATM)

Retrieved from "https://ccga.io/index.php?title=HAEM5:Ataxia-telangiectasia_syndrome&oldid=14629"